Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab in pediatric moderately to severely active Crohn's disease
NL-OMON59661Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of guselkumab in Crohn's disease, sponsored by Janssen Pharmaceutical. Primary endpoints: Clinical remission at Week 52 and Endoscopic response at Week 52. Started Sep 2024; status: recruiting.
02
Drugs
guselkumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON59661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59661.